^
Association details:
| Biomarker: | PIK3CA mutation + MSI-L/dMMR |
|---|---|
| Cancer: | Bladder Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
2226 / 8 - Precise stratification of immunotherapy outcomes using response-associated somatic mutations
Published date:
05/27/2020
Excerpt:
All patients had received at least one dose of an ICI (anti-PD-1/PD-L1, anti-CTLA-4 or both)...we identified 14 ICI-response associated genes (IRAGs) across 6 cancer types. We verified that these IRAGs were predictive rather than prognostic...while 11 IRAGs were associated with worse outcomes in MSI-L tumors. When stratifying by both MSI and TMB status, we found that among TMB-L/MSI-L patients, 3 IRAGs in BLCA and 2 in LUAD were independently associated with worse outcomes.
